Skip to content
Research Article Open access CC BY 4.0

Survival in Patients with Acute Lymphoblastic Leukemia and COVID-19 in Mexico

Patricia Zagoya Martinez, Jose Alejandro Limon Flores, Jose Alfredo Vidal Vidal

International Blood Research & Reviews · pp. 32–39 · Published 2 Jun 2021

10.9734/ibrr/2021/v12i330153

Abstract

Aims: To determine the survival of patients with acute lymphoblastic leukemia and COVID-19. Study Design: Prospective, analytical and relational. Place and Duration of Study: Hematology department, Hospital of Specialties, High Specialty Medical Unit, National Medical Center "Gral. Manuel Avila Camacho", Puebla, Mexico, during the period June 2020-April 2021 Methodology: Patients aged 15 to 64 years, both sexes, with acute lymphoblastic leukemia and a confirmed diagnosis of COVID-19 by PCR. The variables included were; sex, age (groups: 15-20; 21-29; 30-39; 40-49; 50-59; and 60-64), comorbidities, general treatment and hematological treatment response. Survival was determined for the diagnosis of COVID-19 for 11 months, using the Kaplan Meier estimator and the Log-Rak test; Cox regression model (univariate and multivariate); as well as Chi square and V-Cramer with a 95% confidence interval and using the statistical program SPSS Ver. 25. Results: The study consisted of 20 patients, of which 33.3% were women, with an average age of 37.75 ± 11.63 years; The men registered an age of 28.50 ± 18.05 years. Overall survival was 50%, with a lower limit of 101.3 and an upper limit of 242.5 days, with a mean of 171.9 days; and median at 17 days. No significant differences were found in survival regarding sex, comorbidities, general treatment and hematological response. However, mortality in patients with comorbidities was higher (p = 0.051). Conclusion: Survival in patients with acute lymphoblastic leukemia and COVID-19 is low, due to complications that increase mortality, mainly owing to hematological suppression, and even more so with the presence of comorbidities.

Cancer hematological alterations mortality SARS-CoV-2

References (12)

  1. 1 Diabetes is a risk factor for the progression and prognosis of COVID ‐19 [DOI]
  2. 2 Acute lymphoblastic leukemia: a comprehensive review and 2017 update [DOI]
  3. 3 COVID-19: The first documented coronavirus pandemic in history [DOI]
  4. 4 COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus [DOI]
  5. 5 Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study [DOI]
  6. 6 Infection-related complications during treatment for childhood acute lymphoblastic leukemia [DOI]
  7. 7 History of investigation and current classification of coronaviruses (Nidovirales: Coronaviridae) [DOI]
  8. 8 Clinical characteristics and risk factors for mortality in hematologic patients affected by COVID‐19 [DOI]
  9. 9 COVID-19: etiology, clinical picture, treatment [DOI]
  10. 10 Effect of age, comorbidity and remission status on outcome of COVID-19 in patients with hematological malignancies [DOI]
  11. 11 Sex-Specific Associations Between Chemotherapy, Chronic Conditions, and Neurocognitive Impairment in Acute Lymphoblastic Leukemia Survivors: A Report From the Childhood Cancer Survivor Study [DOI]
  12. 12 Reply to “CLL and COVID-19 at the Hospital Clinic of Barcelona: an interim report” Analysis of six hematological centers in Lombardy [DOI]

Cited by 1

Miliary Tuberculosis with Cutaneous Affectations and SARS-CoV-2 Coinfection in Infant: Case Report in Mexico

Ivonne Juarez Reyes, Jose Alfredo Vidal Vidal, Virginia Lora Tellez · Journal of Advances in Medicine and Medical Research · 2022

Related research

Article metrics

Real usage data collected on this platform.

24

Page views

0

PDF downloads

2

Outbound clicks

1

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.